Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 1.00 |
| ▸ | MTNR1B | P49286 | 7/20 | 1.00 |
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1970411 | 1.00 | MTNR1A (1.00) | MTNR1AMTNR1BMAOAMAOBCA1 | |
| SCHEMBL1029693 | 0.87 | MTNR1A (0.77) | MTNR1AMTNR1BCA1CA2 | |
| SCHEMBL30595323 | 0.87 | MTNR1A (0.77) | MTNR1AMTNR1BCA1CA2 | |
| SCHEMBL30612411 | 0.84 | MTNR1A (0.73) | MTNR1AMTNR1BMAOAMAOBCA1 | |
| SCHEMBL9851515 | 0.84 | MTNR1A (0.73) | MTNR1AMTNR1BMAOAMAOBCA1 | |
| SCHEMBL3897095 | 0.83 | MTNR1A (0.71) | MTNR1AMTNR1BMAOAMAOBCA1 | |
| SCHEMBL827706 | 0.82 | MTNR1A (1.00) | MTNR1AMTNR1BMAOAMAOBDRD2 | |
| SCHEMBL26763719 | 0.82 | MTNR1A (0.69) | MTNR1AMTNR1BMAOAMAOBCA1 | |
| SCHEMBL2597383 | 0.82 | MTNR1A (1.00) | MTNR1AMTNR1BMAOAMAOBDRD2 | |
| SCHEMBL4112887 | 0.82 | MTNR1A (1.00) | MTNR1AMTNR1BMAOAMAOBDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
| CN-109071446-B | Organic reaction in aqueous solution in the presence of hydroxyalkyl (alkyl) cellulose or alkylcellulose | 艾伯维德国有限责任两合公司 | 2022-06-21 | — | — | CN | disclosed |
| US-11312668-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | ABBVIE INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-11312668-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | ABBVIE INC. (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2021226276-A2 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| US-20210017100-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | AbbVie Deutschland GmbH & Co. KG (DE) | 2021-01-21 | — | — | US | disclosed |
| US-20210017100-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | AbbVie Deutschland GmbH & Co. KG (DE) | 2021-01-21 | — | — | US | disclosed |
| US-10836688-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | ABBVIE INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-10836688-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | ABBVIE INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-7612104-B2 | Bicyclic aryl-sulfonic acid [1,3,4]-thiadiazol-2-yl-amides, processes for their preparation, pharmaceutical compositions and methods for their use | SANOFI-AVENTIS (FR) | 2009-11-03 | — | — | US | disclosed |
| US-20080293780-A1 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | SANOFI-AVENTIS (FR) | 2008-11-27 | — | — | US | disclosed |
| US-5681961-A | TREATMENT AND/OR PREVENTION OF THROMBOEMBOLIC DISORDERS, ARTERIOSCLEROSIS, METASTASIS. ISCHEMIA, ASTHMA, ALLERGIES | DR. KARL THOMAE GMBH (DE) | 1997-10-28 | — | — | US | disclosed |
| EP-0397044-B1 | Arylsulfonamides, medicines containing these compounds and process for their preparation | THOMAE GMBH DR K (DE) | 1995-12-27 | — | — | EP | disclosed |
| US-5426119-A | Thromboxane antagonists | DR. KARL THOMAE GMBH (DE) | 1995-06-20 | — | — | US | disclosed |
| US-5294626-A | Thromboxane synthesis inhibitors and anticoagulants | DR. KARL THOMAS GMBH (DE) | 1994-03-15 | — | — | US | disclosed |
| US-5151446-A | Neurological disorders or cardiovascular disorders | NORTHWESTERN UNIVERSITY (US) | 1992-09-29 | — | — | US | disclosed |
| US-5071875-A | Nervous system, psychological disorders; sleep cycle, skin dis coloration | NORTHWESTERN UNIVERSITY (US) | 1991-12-10 | — | — | US | disclosed |
| EP-0420064-A2 | Substituted 2-amidotetralins as melatonin agonists and antagonists | NORTHWESTERN UNIVERSITY (US) | 1991-04-03 | — | — | EP | disclosed |
| EP-0397044-A2 | Arylsulfonamides, medicines containing these compounds and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1990-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293780-A1 | BICYCLIC ARYL-SULFONIC ACID [1,3,4]-THIADIAZOL-2-YL-AMIDES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | PPARG, PPARA, PPARD | MTNR1A 298/4885MTNR1B 373/4885MAOA 2850/4885 |
| US-20210017100-A1 | ORGANIC REACTIONS CARRIED OUT IN AQUEOUS SOLUTION IN THE PRESENCE OF A HYDROXYALKYL(ALKYL)CELLULOSE OR AN ALKYLCELLULOSE | LIPA, ALG1, CEL | MTNR1A 4854/4885MTNR1B 4786/4885MAOA 874/4885 |
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | MTNR1A 823/4885MTNR1B 815/4885MAOA 1527/4885 |
| US-10836688-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | LIPA, ALG1, CEL | MTNR1A 4854/4885MTNR1B 4786/4885MAOA 874/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | MTNR1A 773/4885MTNR1B 747/4885MAOA 1562/4885 |
| US-11312668-B2 | Organic reactions carried out in aqueous solution in the presence of a hydroxyalkyl(alkyl)cellulose or an alkylcellulose | LIPA, ALG1, CEL | MTNR1A 4854/4885MTNR1B 4786/4885MAOA 874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.